MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients.

Xichun Hu,Jifang Gong,Dongmei Ji,Lin Shen,Yufeng Li,Mengde Wang,Yingjie Huang,Zhenzhong Xia,Lingmin Lu,John Huang,Li Xu,Jenny Jing Li,Yuntao Wan,Xueming Qian

MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients.

2020

Xichun Hu
Jifang Gong
Dongmei Ji
Lin Shen
Yufeng Li
Mengde Wang
Yingjie Huang
Zhenzhong Xia
Lingmin Lu
John Huang
Li Xu
Jenny Jing Li
Yuntao Wan
Xueming Qian

e15011Background: MSB2311 is a novel humanized programmed death-ligand 1 (PD-L1) antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumo...

Keywords:

Cancer
programmed death
Oncology
phase i study
Internal medicine
Pathology
Medicine
Antibody
Tolerability

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations